Company Overview
Phaos Technology Holdings (Cayman) Limited operates within the healthcare sector, specifically focusing on the medical devices industry through its subsidiary, Phaos Technology Pte. Ltd. The company is dedicated to the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products based in Singapore, offering Optonano which enables users to view live and still imagery. This micro-cap enterprise currently maintains a market capitalization of $21.93M and employs a workforce of 25 individuals. With an annual revenue of $167,707, the company operates at a very small scale, indicating that it is in an early-stage development phase rather than a mature commercial entity. The disparity between the $21.93M market cap and the $167,707 in revenue suggests that the market places a significant premium on the company's future potential and intellectual property rather than its current operational earnings.
Financial Health
The company reported a revenue of $167,707 for the trailing twelve months, yet it simultaneously posted a net income of $-5,137,064, revealing a severe cost structure where expenses drastically exceed top-line income. This negative net income is further reflected in an EBITDA of $-3,869,313, which demonstrates that core operational activities are currently generating significant losses before interest and taxes. Free cash flow stands at $-1,657,362, indicating that the company is burning through cash reserves and lacks immediate financial flexibility to fund operations without external capital injections. Profitability metrics are deeply distressed, with a gross margin of 22.1%, an operating margin of -1897.8%, and a profit margin of 0.0%, signaling that the company is unable to convert sales into sustainable profits at this time. Liquidity is constrained by a current ratio of 0.40, which indicates that the company's current assets are insufficient to cover its current liabilities, presenting a high risk of short-term solvency issues. The balance sheet shows cash holdings of $177,660 against total debt of $3.26M, while the debt-to-equity ratio is listed as N/A, suggesting a leveraged or equity-deficient position relative to obligations. Return on Equity is reported at -1073.1% and Return on Assets at -71.2%, metrics that reveal management is currently ineffective at generating positive returns on the capital invested in the business.
Valuation Assessment
Valuation multiples for Phaos Technology Holdings are distorted by the absence of earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E also as N/A. The absence of a trailing P/E implies that traditional earnings-based valuation methods are not applicable, while the forward P/E of N/A suggests the market does not yet anticipate positive earnings in the immediate future. The price-to-book ratio is reported at -27.07, a figure that indicates the market is pricing the company below its book value, often seen in distressed or pre-profitable biotech and medical device firms. Additionally, the price-to-sales ratio stands at 130.77 and the EV/EBITDA is -11.44, suggesting that investors are valuing the company primarily on potential future growth rather than current sales efficiency or earnings power. Price metrics show a 52-Week High of $7.39 and a 52-Week Low of $0.53, placing the current trading range within a highly volatile band defined by these extremes. The beta is listed as N/A, meaning that the historical volatility relative to the broader market cannot be quantified with this metric.
Growth & Income
Revenue growth year-over-year is reported at -93.1%, while earnings growth is N/A due to the company's lack of positive earnings history. The negative revenue growth indicates a contraction in sales compared to the prior year, and since earnings are already negative, the concept of earnings growing faster or slower than revenue is not currently applicable in a traditional sense. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all available resources to reinvest into growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage companies that must allocate all capital toward product development and commercialization to achieve profitability. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting the high-risk nature of a pre-revenue or loss-making medical device manufacturer.